nach oben

Current Cardiology Reports

Erschienen in:

10.02.2024 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Update on the Role of Colchicine in Cardiovascular Disease

verfasst von: Darcy Banco, Mohammad Mustehsan, Binita Shah

Erschienen in: Current Cardiology Reports | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review focuses on the use of colchicine to target inflammation to prevent cardiovascular events among those at-risk for or with established coronary artery disease.

Recent Findings

Colchicine is an anti-inflammatory drug that reduces cardiovascular events through its effect on the IL-1β/IL-6/CRP pathway, which promotes the progression and rupture of atherosclerotic plaques. Clinical trials have demonstrated that colchicine reduces cardiovascular events by 31% among those with chronic coronary disease, and by 23% among those with recent myocardial infarction. Its ability to dampen inflammation during an acute injury may broaden its scope of use in patients at risk for cardiovascular events after major non-cardiac surgery.

Summary

Colchicine is an effective anti-inflammatory therapy in the prevention of acute coronary syndrome. Ongoing studies aim to assess when, and in whom, colchicine is most effective to prevent cardiovascular events in patients at-risk for or with established coronary artery disease.

Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106(23):2894–900. https://doi.org/10.1161/01.cir.0000042674.89762.20.CrossRefPubMed

Quillard T, Araújo HA, Franck G, Shvartz E, Sukhova G, Libby P. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: Implications for superficial erosion. Eur Heart J. 2015;36(22):1394–404. https://doi.org/10.1093/eurheartj/ehv044.CrossRefPubMedPubMedCentral

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: A collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293–301. https://doi.org/10.1016/s0140-6736(23)00215-5.CrossRefPubMed

•• Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62. https://doi.org/10.1056/NEJMoa1809798. The CANTOS randomized control trial demonstrated that the IL-1B inhibitor canakinumab reduced cardiovascular events among those with AMI and elevated hs-CRP with a concurrent increase in fatal infections.CrossRefPubMed

Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458–64. https://doi.org/10.3899/jrheum.111533.CrossRefPubMedPubMedCentral

Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: A cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674–9. https://doi.org/10.1136/annrheumdis-2015-207984.CrossRefPubMed

•• Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505. https://doi.org/10.1056/NEJMoa1912388. The COLCOT randomized control trial demonstrated that colchicine reduced cardiovascular events by 23% among those with recent AMI.CrossRefPubMed

•• Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47. https://doi.org/10.1056/NEJMoa2021372. LoDoCo-2 randomized control trial showed that colchicine reduced cardiovascular events by 31% among those with chronic coronary disease.CrossRefPubMed

10.

Shah B, Toprover M, Crittenden DB, Jeurling S, Pike VC, Krasnokutsky S, et al. Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020;36(11):1722–8. https://doi.org/10.1016/j.cjca.2020.05.026.CrossRefPubMed

11.

Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594–604. https://doi.org/10.1161/circulationaha.110.982777.CrossRefPubMed

12.

Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: Insights from the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017;10(9). https://doi.org/10.1161/circinterventions.117.004981.CrossRefPubMedPubMedCentral

13.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319–28. https://doi.org/10.1016/s0140-6736(17)32814-3.CrossRefPubMed

14.

Martínez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128. https://doi.org/10.1161/jaha.115.002128.CrossRefPubMedPubMedCentral

15.

• Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ Cardiovasc Interv. 2020;13(4):e008717. https://doi.org/10.1161/circinterventions.119.008717. This randomized control trial demonstrated for the first time that colchicine can dampen the inflammatory response to acute injury.CrossRefPubMedPubMedCentral

16.

Toprover M, Shah B, Oh C, Igel TF, Romero AG, Pike VC, et al. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: A prospective observational study. Arthritis Res Ther. 2020;22(1):169. https://doi.org/10.1186/s13075-020-02260-6.CrossRefPubMedPubMedCentral

17.

Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J. 2017;81(8):1174–82. https://doi.org/10.1253/circj.CJ-16-0949.CrossRefPubMed

18.

Bakhta O, Blanchard S, Guihot AL, Tamareille S, Mirebeau-Prunier D, Jeannin P, et al. Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction. J Cardiovasc Pharmacol Ther. 2018;23(5):446–55. https://doi.org/10.1177/1074248418763611.CrossRefPubMed

19.

Forrat R, Sebbag L, Ferrera R, Hadour G, Canet E, Tabib A, et al. Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion. J Cardiovasc Pharmacol. 1996;27(6):876–83. https://doi.org/10.1097/00005344-199606000-00016.CrossRefPubMed

20.

Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96(2):994–1002. https://doi.org/10.1172/jci118147.CrossRefPubMedPubMedCentral

21.

Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X, et al. Colchicine Alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway. Oxid Med Cell Longev. 2020;2020:9173530. https://doi.org/10.1155/2020/9173530.CrossRefPubMedPubMedCentral

22.

Meyer-Lindemann U, Mauersberger C, Schmidt AC, Moggio A, Hinterdobler J, Li X, et al. Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation. Front Immunol. 2022;13:898690. https://doi.org/10.3389/fimmu.2022.898690.CrossRefPubMedPubMedCentral

23.

Kiraz S, Ertenli I, Arici M, Calgüneri M, Haznedaroglu I, Celik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol. 1998;16(6):721–4.PubMed

24.

Bauriedel G, Heimerl J, Beinert T, Welsch U, Höfling B. Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coron Artery Dis. 1994;5(6):531–9.PubMed

25.

Abu-Fanne R, Stepanova V, Litvinov RI, Abdeen S, Bdeir K, Higazi M, et al. Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability. Blood. 2019;133(5):481–93. https://doi.org/10.1182/blood-2018-07-861237.CrossRefPubMedPubMedCentral

26.

Mori H, Taki J, Wakabayashi H, Hiromasa T, Inaki A, Ogawa K, et al. Colchicine treatment early after infarction attenuates myocardial inflammatory response demonstrated by (14)C-methionine imaging and subsequent ventricular remodeling by quantitative gated SPECT. Ann Nucl Med. 2021;35(2):253–9. https://doi.org/10.1007/s12149-020-01559-3.CrossRefPubMed

27.

Aimo A, Martinez-Falguera D, Barison A, Musetti V, Masotti S, Morfino P, et al. Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction. J Cardiovasc Med (Hagerstown). 2023;24(11):840–6. https://doi.org/10.2459/jcm.0000000000001554.CrossRefPubMed

28.

Schwarz N, Fernando S, Chen YC, Salagaras T, Rao SR, Liyanage S, et al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. Faseb J. 2023;37(4):e22846. https://doi.org/10.1096/fj.202201469R.CrossRefPubMed

29.

Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805–7. https://doi.org/10.1016/j.amjcard.2006.10.039.CrossRefPubMed

30.

Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: A pilot study in healthy subjects. Inflammation. 2016;39(1):182–9. https://doi.org/10.1007/s10753-015-0237-7.CrossRefPubMed

31.

•• Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):305–16. https://doi.org/10.1016/j.jcmg.2017.08.013. This observational trial showed that colchicine reduced low-attenuation plaque burden on coronary CT and reduced hs-CRP at one year among those with recent AMI.CrossRefPubMed

32.

Langevitz P, Livneh A, Neumann L, Buskila D, Shemer J, Amolsky D, et al. Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J. 2001;3(1):9–12.PubMed

33.

•• Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10. https://doi.org/10.1016/j.jacc.2012.10.027. LoDoCo showed that colchicine reduced the rate of cardiovascular events, driven by reduction in AMI, with a number-needed-to-treat of 11 patients.CrossRefPubMed

34.

Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome. J Am Coll Cardiol. 2021;78(9):859–66. https://doi.org/10.1016/j.jacc.2021.06.037.CrossRefPubMed

35.

Silvis MJM, Fiolet ATL, Opstal TSJ, Dekker M, Suquilanda D, Zivkovic M, et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93–100. https://doi.org/10.1016/j.atherosclerosis.2021.08.005.CrossRefPubMed

36.

Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation. 2015;132(15):1395–403. https://doi.org/10.1161/circulationaha.115.017611.CrossRefPubMed

37.

•• Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS randomized clinical trial. Circulation. 2020;142(20):1890–900. https://doi.org/10.1161/circulationaha.120.050771.The COPS randomized control trial did not demonstrate a reduction in cardiovascular events at one year when colchicine was administered to those with recent AMI but did show a previously unobserved increase in non-cardiovascular deaths.CrossRefPubMed

38.

•• Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, et al. Colchicine in patients with acute coronary syndrome: Two-year follow-up of the Australian COPS randomized clinical trial. Circulation. 2021;144(19):1584–6. https://doi.org/10.1161/circulationaha.121.054610. This two year follow up of the COPS trial showed that colchicine reduced cardiovascular events among those with recent AMI.CrossRefPubMed

39.

Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41(42):4092–9. https://doi.org/10.1093/eurheartj/ehaa659.CrossRefPubMedPubMedCentral

40.

Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35. https://doi.org/10.1056/NEJMoa1002358.CrossRefPubMed

41.

O’Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19(7):1597–600. https://doi.org/10.1016/0735-1097(92)90624-v.CrossRefPubMed

42.

Rab ST, King SB 3rd, Roubin GS, Carlin S, Hearn JA, Douglas JS Jr. Coronary aneurysms after stent placement: A suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J Am Coll Cardiol. 1991;18(6):1524–8. https://doi.org/10.1016/0735-1097(91)90685-3.CrossRefPubMed

43.

Freed M, Safian RD, O’Neill WW, Safian M, Jones D, Grines CL. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;76(16):1185–8. https://doi.org/10.1016/s0002-9149(99)80334-8.CrossRefPubMed

44.

Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679–85. https://doi.org/10.1016/j.jacc.2013.01.055.CrossRefPubMed

45.

Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc. 2021;10(1):e018993. https://doi.org/10.1161/jaha.120.018993.CrossRefPubMed

46.

Shah B, Smilowitz NR, Xia Y, Feit F, Katz SD, Zhong J, et al. Major adverse cardiovascular events after colchicine administration before percutaneous coronary intervention: Follow-up of the colchicine-PCI trial. Am J Cardiol. 2023;204:26–8. https://doi.org/10.1016/j.amjcard.2023.07.029.CrossRefPubMed

47.

•• Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J. Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: The COPE-PCI pilot trial. Circ Cardiovasc Interv. 2021;14(5):e009992. https://doi.org/10.1161/circinterventions.120.009992. This randomized control pilot trial showed that colchicine administered peri-procedurally among those undergoing percutaneous coronary intervention reduced the incidence of myocardial injury when given 6-24 hours in advance.CrossRefPubMed

48.

Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé MP, Blondeau L, et al. Colchicine for secondary prevention of cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776–85. https://doi.org/10.1016/j.cjca.2020.10.006.CrossRefPubMed

49.

Kofler T, Kurmann R, Lehnick D, Cioffi GM, Chandran S, Attinger-Toller A, et al. Colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized trials. J Am Heart Assoc. 2021;10(16):e021198. https://doi.org/10.1161/jaha.121.021198.CrossRefPubMedPubMedCentral

50.

Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42(28):2765–75. https://doi.org/10.1093/eurheartj/ehab115.CrossRefPubMed

51.

Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. https://doi.org/10.1016/j.amjmed.2021.07.025.CrossRefPubMed

52.

Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486–95. https://doi.org/10.1093/ehjqcco/qcaa045.CrossRefPubMed

53.

Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8. https://doi.org/10.1002/art.27327.CrossRefPubMed

54.

McCormick N, Wallace ZS, Yokose C, Jorge A, Sacks CA, Hsu J, et al. Prolonged increases in public-payer spending and prices after unapproved drug initiative approval of colchicine. JAMA Intern Med. 2021;181(2):284–7. https://doi.org/10.1001/jamainternmed.2020.5017.CrossRefPubMed

55.

Lee SY, Jeong YH, Yun KH, Cho JY, Gorog DA, Angiolillo DJ, et al. P2Y(12) Inhibitor monotherapy combined with colchicine following PCI in ACS patients: The MACT Pilot Study. JACC Cardiovasc Interv. 2023;16(15):1845–55. https://doi.org/10.1016/j.jcin.2023.05.035.CrossRefPubMed

56.

Dubé MP, Legault MA, Lemaçon A, Lemieux Perreault LP, Fouodjio R, Waters DD, et al. Pharmacogenomics of the efficacy and safety of colchicine in COLCOT. Circ Genom Precis Med. 2021;14(2):e003183. https://doi.org/10.1161/circgen.120.003183.CrossRefPubMedPubMedCentral

Titel: Update on the Role of Colchicine in Cardiovascular Disease
verfasst von: Darcy Banco
Mohammad Mustehsan
Binita Shah
Publikationsdatum: 10.02.2024
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 4/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-024-02026-5

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Update on the Role of Colchicine in Cardiovascular Disease

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Updates on Non-Statin LDL-Lowering Therapy

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention

The Global Epidemic of Metabolic Fatty Liver Disease

Open Surgical Therapy for Peripheral Artery Disease

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie